High yields in suspension CHO & HEK-293
- Amazing protein and antibody production yields
- Cost-effective Transient Gene Expression using lower plasmid DNA amount
- Compatible with various mammalian expression media & cells systems
- Compliant with biomanufacturing guidelines
- Adapted to high density cell systems
- Chemically defined and animal derived component free
Suspension CHO, HEK-293, and derivatives
|Number of transfections|
1 mL of FectoPRO® is sufficient to transfect 800 ml to more than 1 liter of cell culture
5°C ± 3°C, stable for 1 to 2 years when stored appropriately
For the first time, achieve superior protein yields using transient transfection and gene expression.
FectoPRO® Transfection kit is specifically designed for enhanced Transient Gene Expression (TGE) in suspension CHO and HEK-293 cells in various serum-free media, using low DNA amount (< 1 µg/ml of cell culture).
FectoPRO®-mediated transfection process is easily scalable from a few ml to several liters of cell culture, ensuring robust reproducible protein production. Increased productivity and low DNA amount requirement make FectoPRO® a cost-effective solution for bioproduction processes.
GEN article: Upping CHO and HEK-293 Cell Productivity
Cell Culture Dish Article with Protéogénix: Improved Protein yields in CHO and HEK293 cells using a dedicated transfection reagent: FectoPRO®
|Product||Reference Number||Transfection Reagent||Expression Booster||Expression Medium|
|FectoPRO® Reagent||116-001||1 ml||1 ml||-|
|FectoPRO® Reagent||116-010||10 ml||10 ml||-|
|FectoPRO® Reagent||116-040||4 x 10 ml||4 x 10 ml||-|
|FectoCHO® CD Medium||716-01L||-||-||1 L|
|FectoCHO® CD Medium||716-06L||-||-||6 x 1 L|
|FectoCHO® Expression System||716-01LKIT||1 ml||1 ml||1 L|
|FectoCHO® Expression System||716-06LKIT||5 x 1 mL||5 x 1 mL||6 x 1 L|
Amazing protein yields
FectoPRO® enables amazingly high protein and antibody yields in both CHO and HEK-293 cells grown in suspension in serum-free media (Fig 1).
FectoPRO® largely outperforms other transfection reagents such as linear PEI commonly used in Bioproduction processes in terms of transfection efficiency (Fig. 2), leading to superior protein production yields (Fig. 3).
Cost-effective: uses low plasmid DNA amounts
High quality plasmid DNA preparation can be very costly, especially when large DNA amounts and many plasmids are required for large-scale protein production. FectoPRO® saves 40 to 60% on DNA cost by using 0.4 to 0.6 µg DNA / 106 cells / ml of cell culture; hence making this kit an affordable and economical solution for Bioproduction processes.
Sustained protein production
The duration of protein production processes has increased in the past few years, and most of the protein production processes now last 1-2 weeks to obtain optimal amount of produced protein. FectoPRO® has been developed to ensure sustained protein production over several days, while maintaining high cell viability for longer lasting protein production (Fig. 4.).
Streamline your bioproduction process with a robust protocol that is easily adapted to various culture vessels. FectoPRO®-mediated transfection can be scaled linearly from 30 ml up to liters of cell culture without protocol adaptation (Fig. 5.).
Reproducible production yields
FectoPRO® is manufactured and formulated using a highly controlled production process. This ensures highly reproducible results from experiment to experiment. Moreover, in order to meet current regulatory guidelines, FectoPRO® is released using advanced quality controls including a specification for protein productivity that guarantees excellent lot-to-lot consistency (Fig. 6).
Compatible with mammalian expression systems
Unlike other commercially available reagents, FectoPRO® transfection kit is suitable for both CHO and HEK-293 cells (Fig. 2 and 3). The reagent is compatible with various media formulations; hence lab implementation is easy and straightforward (Fig. 7, Table 2).
FreeStyleTM, CD FortiCHOTM, CD OptiCHOTM, Expi293TM, ExpiCHOTM and CD293 are trademarks of Gibco®.
Pro-CHOTM, PowerCHOTM and Pro293TM are trademarks of LonzaTM Group.
HyCloneTM, HyCellTM and TransFxTM are trademarks of GE HealthcareTM.
BalanCD® and TransfectoryTM are trademarks of Irvine ScientificTM.
FectoPRO® is also perfectly suited for virus production.
If you have any questions regarding FectoPRO®, please visit our dedicated Frequently asked questions or contact us at firstname.lastname@example.org.
Transient protein production
Protein production consists in overexpressing a recombinant protein or peptide in a cell line at small / medium to large scale. The biomolecules produced can be used for research purposes like structural characterization all the way down to therapeutic or medical applications.
Available Application Notes:
- Optimization of Glycoprotein Expression by Transient Transfection in HEK 293F/S suspension cells
- Superior protein yields in suspension CHO cells using FectoPRO®-mediated transient transfection in CELLSTAR® CELLreactor™
- Improved Protein yields in CHO cells using a novel transfection reagent for TGE: FectoPRO®
- Improving expression and purification of mAb using FectoCHO® Expression System and MabXpure™
High density cell systems for protein production using FectoPRO®
Recombinant protein production for therapy and diagnostic applications is mainly achieved using HEK-293 and CHO cells cultivated in suspension cultures without serum. The latter has been removed from raw materials for various reasons (costs, downstream purification steps, reproducibility…) while culture in suspension has been implemented to increase productivity. Improvements in culture processes and cell line engineering led to the generation of high-density mammalian transient protein expression systems.
Polyplus-transfection has collected many scientific publications in which FectoPRO® was used to perform sucessful transient transfection:
Cupo, A., Cruz Portillo, V. M., Gelfand, P., Yasmeen, A., Klasse, P. J., Moore, J. P. (2019). Optimizing the production and affinity purification of HIV-1 envelope glycoprotein SOSIP trimers from transiently transfected CHO cells, PLoS ONE 14(4), doi: 10.1371/journal.pone.0215106.
Carravilla, P., Chojnacki, J., Rujas, E., Insausti, S., Largo, E., Waithe, D., Apellaniz, B., Sicard, T., Julien, J. P., Eggeling, C., Nieva, J. L. (2019). Molecular recognition of the native HIV-1 MPER revealed by STED microscopy of single virions, Nat Commun 10 78, doi: 10.1038/s41467-018-07962-9.
Cooke H.A., Arndt J., Quan C., Shapiro R.I., Wen D., Foley S., Vecchi M.M., Preyer M. (2018). EFab domain substitution as a solution to the light-chain pairing problem of bispecific antibodies. MABs, doi: 10.1080/19420862.2018.1519631.
Tveriakhina, L., Schuster-Gossler, K., Jarrett, S. M., Andrawes, M. B., Rohrbach, M., Blacklow, S. C., Gossler, A. (2018). The ectodomains determine ligand function in vivo and selectivity of DLL1 and DLL4 toward NOTCH1 and NOTCH2 in vitro, Elife 7, doi: 10.7554/eLife.40045.
Toczydlowska-Socha, D., Zielinska, M. M., Kurkowska, M., Astha,, Almeida, C. F., Stefaniak, F., Purta, E., Bujnicki, J. M. (2018). Human RNA cap1 methyltransferase CMTr1 cooperates with RNA helicase DHX15 to modify RNAs with highly structured 5′ termini, Philos Trans R Soc Lond B Biol Sci 373, doi: 10.1098/rstb.2018.0161.
Lu, J., Wang, R., Xia, B., Yu, Y., Zhou, X., Yang, Z., Huang, P. (2018). Potent Neutralization Ability of a Human Monoclonal Antibody Against Serotype 1 Dengue Virus, Front Microbiol g 1214, doi: 10.3389/fmicb.2018.01214.
Darricarrere, N., Pougatcheva, S., Duan, X., Rudicell, R. S., Chou, T. H., DiNapoli, J., Ross, T. M., Alefantis, T., Vogel, T. U., Kleanthous, H., Wei, C. J., Nabel, G. J. (2018). Development of a Pan-H1 Influenza Vaccine, J Virol, doi: 10.1128/JVI.01349-18.
Chen, Y. H., Narimatsu, Y., Clausen, T. M., Gomes, C., Karlsson, R., Steentoft, C., Spliid, C. B., Gustavsson, T., Salanti, A., Persson, A., Malmstrom, A., Willen, D., Ellervik, U., Bennett, E. P., Mao, Y., Clausen, H., Yang, Z. (2018). The GAGOme: a cell-based library of displayed glycosaminoglycans, Nat Methods, doi: 10.1038/s41592-018-0086-z.
Moyo, T., Ereno-Orbea, J., Jacob, R. A., Pavillet, C. E., Kariuki, S. M., Tangie, E. N., Julien, J. P., Dorfman, J. R. (2018). Molecular basis of unusually high neutralization resistance in tier 3 HIV-1 strain 253-11, J Virol, doi: 10.1128/JVI.02261-17.
Lena Tveriakhina, Karin Schuster-Gossler, Sanchez M. Jarrett, Marie B. Andrawes, Meike Rohrbach, Stephen C. Blacklow, Achim Gossler (2018).The ectodomains determine ligand function in vivo and selectivity of DLL1 and DLL4 toward NOTCH1 and NOTCH2 in vitro, eLIFE, doi: 10.7554/eLife.40045.
Batonick, M., Kiss, M.M., Fuller, E.P., Magadan, C.M., Holland, E.G., Zhao, Q., Wang, D., Kay, B.K., Weiner, M.P. (2016). pMINERVA: A donor-acceptor system for the in vivo recombineering of scFv into IgG molecules, J Immunol Methods, doi: 10.1016/j.jim.2016.02.003.
Ferreira de Freitas, R., Eram, M. S., Smil, D., Szewczyk, M. M., Kennedy, S., Brown, P. J., Santhakumar, V., Barsyte-Lovejoy, D., Arrowsmith, C. H., Vedadi, M., Schapira, M. (2016). Discovery of a Potent and Selective Coactivator Associated Arginine Methyltransferase 1 (CARM1) Inhibitor by Virtual Screening, J Med Chem, doi: 10.1021/acs.jmedchem.6b00668.
Li, M., Yang, S., Xu, D. (2016). Heparan Sulfate Regulates the Structure and Function of Osteoprotegerin in Osteoclastogenesis, J Biol Chem, doi: 10.1074/jbc.M116.751974.
“The solution we identified was to eliminate the need for the ExpiCHO-S cell Enhancer component by using instead a different transfection medium culture system, FectoPRO® with Booster, with the ExpiCHO-S cells. We also note that the FectoPRO® with Booster system is ~40% cheaper than its ExpiFectamine CHO with Feed and Enhancer counterpart. This methodology change would therefore also provide cost savings.”
Cupo et al, 2019, doi: 10.1371/journal.pone.0215106.
“In our hands, FectoPRO® gives the highest protein production yields we ever reached using transient transfection. Our company offers custom services including protein production in mammalian cells. Being able to produce a lot more protein without revisiting our expression system opens a whole new range of possibilities for our antibody and protein production services.”
Philippe F., ProteoGenix SAS, France
“I have to admit I had low expectations for FectoPRO®. Perhaps a modest improvement in transfection … an extra 5-10%. J. did her first experiment yesterday and analyzed it today and the result was remarkable. I’m shocked by both the efficiency of transfection and the brightness of the GFP.”
Thomas C., Biotech, Cambridge, MA, United States
“FectoPRO® yields transient expression titers in HEK, matching or exceeding those from other suppliers, but at a fraction of the price.”
James L., Biotech company, United States
“2 x the yield for half the amount of transfection reagent = 4 x less cost. It is also very easy to use.”
Jean-Philippe J., Hospital for Sick Children, Canada
FectoPRO® is compliant with biomanufacturing guidelines. Indeed, FectoPRO® is guaranteed free of animal-origin components, and is chemically defined. Systematic lot management and release testing is performed for each lot produced. Furthermore FectoPRO® transfection kit undergoes advanced quality controls: protein productivity, cell viability, and complete sterility.
In addition, Polyplus-transfection® is ISO 9001 Quality Management System accredited since 2002; this level of certification assures global customers that the supplier has established reliable and effective processes for product development, manufacturing, sales and customer support.